10th Conference on Retroviruses and Opportunistic Infections Boston, MA USA - February 10 -14, 2003

Conf Retroviruses Opportunistic Infect 2003 Feb 10-14;10th: abstract no. 6
Chan J, Ferris R , Roberts G, Short S, Weaver K, Hazen R, Creech K, Clair MS, Dornsife R, Freeman G, Tidwell J, Romines K, Schaller L, Cowan J, Boone L
GlaxoSmithKline, Inc, Research Triangle Park, NC

BACKGROUND: From a collection of 250 benzophenones that were synthesized based on structure-activity relationship and modeling, analogs have been identified which are potent inhibitors of wild-type and NNRTI-resistant strains of HIV-1. Studies were undertaken in enzyme, cell-based anti-viral, and cytotoxicity assays to determine the suitability of 3 analogs, GW4751, GW4511 and GW3011, as leads for a new generation NNRTI capable of treating current NNRTI-resistant strains.

METHODS: Wild-type HIV, 20 NNRTI-resistant and 7 NRTI-resistant strains were assessed in one or more in vitro assays including HeLa-MAGI, MT4, HOS and PBL. Activity against wild-type and NNRTI-resistant mutant reverse transcriptase (RT) enzyme was assessed in a continuous time-resolved fluorescence assay. Effect on IC₅₀ due to serum protein binding was determined in HeLa MAGI assays. Cell cytotoxicity was assessed in human leukemic cell lines (IM9, MT4, U-973, Molt-4) by MTT assay and in primary human bone marrow progenitor cells by colony formation. Serial passage was carried out in MT4 cells.

RESULTS: The IC₅₀ values for GW4751, GW4511 and GW3011 were ≤ 2nM versus wild-type HIV-1 in the HeLa MAGI assay. The highest IC₅₀ in a panel of 20 NNRTI-resistant mutants was 16nM for GW4511, 21nM for GW3011, and 34nM for GW4751. These compounds inhibited wild-type and mutant RT enzyme in biochemical assays with IC₅₀s that ranged from < 3-17nM. Forty-five percent (45%) human serum and/or 0.8mg/ml α1-acid glycoprotein resulted in a modest increase in IC₅₀ (4-8X). Cytotoxicity (CCIC₅₀) of all 3 compounds was similar and ranged from 12uM to > 28uM (limited by solubility) among 4 human leukemic cell lines. Human bone marrow progenitor assays (CFU-GM and BFU-E) demonstrated a CCIC₅₀ > 10 uM (highest concentration tested) for all 3 compounds. Eight (8) passages in escalating concentrations of GW4511 selected for mutational changes at RT loci V106A, E138K, and F227L.

CONCLUSIONS: Benzophenone analogues GW4751, GW4511, and GW3011 are potent new NNRTIs active against both wild-type virus and a broad-spectrum of NNRTI-associated mutant viruses including those known to be highly resistant to currently available NNRTIs. The mutations selected during passage with GW4511 are known to be associated with NNRTI resistance. [j1] The effects on IC₅₀ of human serum protein binding were modest and cytotoxicity was low. These benzophenone compounds represent important lead molecules for the discovery of a potent new generation NNRTI.

030210
6

Copyright © 2003 - Foundation for Retrovirology and Human Health. Reproduction of this abstract (other than one copy for personal reference) must be cleared through the Foundation for Retrovirology and Human Health. Licensed (AIDSLINE) from National Library of Medicine.